Status:
COMPLETED
Sex Hormones and Blood PCSK9 Levels
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborating Sponsors:
Heart and Stroke Foundation of Ontario
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
18+ years
Brief Summary
This study measures a recently discovered protein named PCSK9 (Proprotein convertase subtilisin kexin 9) in blood to see if it is influenced by male and female sex hormones. PCSK9 has recently been sh...
Detailed Description
Proprotein convertase subtilisin kexin 9 (PCSK9) is a secreted glycoprotein that was first demonstrated to play a role in lipoprotein metabolism in 2003 when several gain-of-function single nucleotide...
Eligibility Criteria
Inclusion
- Males:
- 18 years of age and older for hypogonadal males/males with prostate cancer
- Prior clinical decision to start on testosterone therapy
- Females:
- 30 years of age and older for post-menopausal women
- Prior clinical decision to start on estrogen therapy
Exclusion
- Cognitive impairment, active or chronic hepatic or renal disease, diagnosed diabetes mellitus,alcohol consumption greater than 4 drinks/day
- receiving or needing progestogen therapy for women
Key Trial Info
Start Date :
July 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00848276
Start Date
July 1 2008
End Date
September 1 2010
Last Update
December 8 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ottawa Hospital Riverside Campus
Ottawa, Ontario, Canada, K1H 7W9